Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg \
3 min read
\
\

Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg

21-Mar-2022
Mumbai (Maharashtra) [India], March 21 (ANI/PR Newswire): Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for its Lacosamide Tablets1 USP, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat®2 Tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB, Inc.
21-Mar-2022 Business
\
Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability emerging markets index for the fourth consecutive year \
2 min read
\
\

Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability emerging markets index for the fourth consecutive year

16-Nov-2021
Mumbai (Maharashtra) [India], November 16 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that the company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the fourth consecutive year.
16-Nov-2021 Business
\
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1% \
1 min read
\
\

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%

21-Sep-2021
Mumbai (Maharashtra) [India], September 21 (ANI/PR Newswire): Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc.
21-Sep-2021 Business
\